Edwards Lifesciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Edwards Lifesciences generated cash of $895,800,000, which is less than the previous year. Cash used in financing activities reached the amount of -$711,000,000 last year. Net change in cash is therefore $375,400,000.
Cash Flow
| 2014 | 1.02B | -633M | -153M |
|---|---|---|---|
| 2015 | 549.7M | -316.1M | -158.6M |
| 2016 | 704.4M | -211.7M | -268.5M |
| 2017 | 1.00B | -647.2M | -473.2M |
| 2018 | 926.8M | 76.7M | -1.10B |
| 2019 | 1.17B | -595.8M | -115.6M |
| 2020 | 1.05B | -531.1M | -486.9M |
| 2021 | 1.73B | -1.72B | -356.3M |
| 2022 | 1.21B | 252.3M | -1.58B |
| 2023 | 895.8M | 173.8M | -711M |
EW Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 772.6M | 867.4M | 1.20B | 1.18B | 714.1M | 818.3M | 930.1M | 718.4M | 653.8M | 420.4M |
Operating activities | ||||||||||
Net income | 1.39B | 1.52B | 1.50B | 823.4M | 1.04B | 722.2M | 583.6M | 569.5M | 494.9M | 811.1M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 144.9M | 139.6M | 134.8M | 107.2M | 89.3M | 77.4M | 81.9M | 71.2M | 65.8M | 68.6M |
Stock-based compensation expense | 139.4M | 126.8M | 109.3M | 92.6M | 81.3M | 0 | 61.6M | 56.9M | 49.9M | 48.3M |
| Deferred income tax benefit | 139.4M | 126.8M | 109.3M | 92.6M | 81.3M | 0 | 61.6M | 56.9M | 49.9M | 48.3M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -141.2M | -84.1M | -112.4M | 283.9M | -94.8M | -13M | -3.9M | -56.7M | -38.3M | -26.8M |
Inventories | -289M | -213.4M | 19M | -120.6M | -105.4M | -65.7M | -124M | -65.6M | -67.7M | -30.5M |
Accounts payable | 146M | -21.4M | 195.2M | -84.5M | -63.5M | 192.5M | 85.2M | 74M | 29.4M | 112.9M |
Cash generated by operating activities | 895.8M | 1.21B | 1.73B | 1.05B | 1.17B | 926.8M | 1.00B | 704.4M | 549.7M | 1.02B |
Investing activities | ||||||||||
Purchases Of Investments | -105.5M | -778.9M | -1.89B | -861.7M | -603.1M | -471.9M | -1.34B | -1.07B | -1.31B | -2.13B |
Investments In Property Plant And Equipment | -266.3M | -264.8M | -329.8M | -407.3M | -278.4M | -241.7M | -175.5M | -217.4M | -106.5M | -93.7M |
Acquisitions Net | -95.2M | 0 | 329.8M | 407.3M | -100.2M | -6.2M | -184.6M | -5.7M | -333.7M | -24.1M |
Cash generated by investing activities | 173.8M | 252.3M | -1.72B | -531.1M | -595.8M | 76.7M | -647.2M | -211.7M | -316.1M | -633M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 158.6M | 140.5M | 160.5M | 147M | 113.8M | 103.3M | 87.2M | 113.3M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -879.6M | -1.72B | -512.8M | -625.4M | -263.3M | -795.5M | -763.3M | -662.3M | -280.1M | -300.9M |
Repayments of term debt | -300K | -200K | -7M | -17M | -10M | -1.12B | 176.3M | -31.4M | 1.9M | -239M |
Cash used in financing activities | -711M | -1.58B | -356.3M | -486.9M | -115.6M | -1.10B | -473.2M | -268.5M | -158.6M | -153M |
Net Change In Cash | 375.4M | -94.8M | -332.8M | 15.8M | 465M | -104.2M | -111.8M | 211.7M | 64.6M | 233.4M |
Cash at end of period | 1.14B | 772.6M | 867.4M | 1.20B | 1.17B | 714.1M | 818.3M | 930.1M | 718.4M | 653.8M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |